Retatrutide vs Semaglutide: Obesity Trial Evidence Compared
Retatrutide’s TRIUMPH-1 and semaglutide’s STEP 1 both used placebo comparators. They enrolled different study populations and assessed weight change at different times.
Retatrutide’s TRIUMPH-1 and semaglutide’s STEP 1 both used placebo comparators. They enrolled different study populations and assessed weight change at different times.
A study average combines a range of outcomes. Participants can reach different weight-loss thresholds, experience different adverse events, or discontinue assigned treatment.
A weight-change curve shows estimated group outcomes across scheduled visits. The horizontal axis usually shows time, and the vertical axis shows mean change from baseline.
A placebo group helps researchers estimate how an intervention performed relative to the conditions of that trial. Changes can occur in both arms during follow-up.
Percentage weight change relates the change to baseline weight. Pounds and kilograms describe absolute change. A given percentage represents different amounts at different starting weights.
A responder analysis counts the share of participants who reached a defined reduction from baseline weight. A mean change averages the estimated weight change for a group.
GIP stands for glucose-dependent insulinotropic polypeptide. Retatrutide and tirzepatide both engage the GIP receptor as part of a multi-receptor design.
GLP-1 is one of the three receptors activated by retatrutide. It is also the target of semaglutide, which makes shared receptor activity an easy point of comparison at the molecular level.
LY3437943 is the development code for retatrutide. Registry titles often put the code in parentheses because development programs may use both the code and the generic name.
Retatrutide, also known as LY3437943, is an investigational peptide designed to activate the GLP-1, GIP and glucagon receptors. The three receptor targets are features of the molecule’s design.